Many Lymphoma Patients Missing Out on Best Care

Study shows survival drops when CAR T therapy is not offered to eligible patients

Navigating Survivorship After Bone and Marrow Transplant

Moffitt experts and leukemia survivor share candid insights and support resources

Reaching for the Stars

CAR T therapy transformed one man’s battle with cancer into a story of survival, discovery and impact

Nearly 40 Percent of CAR T Patients Remain in Remission

Many ZUMA-1 participants remain in remission and more than half of those treated remain alive.

New Study Shows CAR T-cell Therapy for Lymphoma Lives up to its Press

Seventeen cancer centers compare real world outcomes of diffuse large B cell lymphoma patients treated with Yescarta® to ZUMA-1 clinical trial data

Father’s Cancer Battle Inspires Son’s Research

Moffitt Physician Co-Led Pivotal Study of CAR-T Therapy

FDA Approves Second CAR T Therapy for Diffuse Large B-Cell Lymphoma

Moffitt Cancer Center is the only center in Florida to offer both FDA approved CAR T therapies, Kymriah™ and Yescarta™

Endeavor